Ontario, Calif., Nov. 27, 2022 — Kiwa Bio-Tech Products Group Corporation (“Kiwa” or the “Company”) (PINK: KWBT). On November 24, 2022, Kiwa announced the change of its independent registered public accounting firm.
The appointment of Tang CPA, PLLC has been approved by the board of directors of the Company. Tang CPA, PLLC is engaged to audit the balance sheet of the Company as of December 31, 2020, December 31, 2021, and December 31, 2022, and the related statement of operations and comprehensive income, shareholder’ equity, and cash flows for the year then ending. Based on Tang CPA, PLLC’s audit, they will issue a written report on the Company’s financial statement and schedules supporting the financial statements (collectively, the “financial statements”), all of which are to be included in the annual report (From 10-k) proposed to be filed by the Company under the Securities Exchange Act of 1934.
Kiwa’s new CEO, Ms. Ziqi Wang Ziqi, states that “The Company is working closely with Tang CPA, PLLC to ensure a seamless transition.”
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company’s actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic, business and environment conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, the execution of its ten-year growth plan, the foreign exchange risk amid the unexpected announcements by the PRC government and various other factors beyond the Company’s control. Kiwa Bio-Tech Products Group Corp. specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
For investor and media inquiries, please contact: